ARF1 and EEF1G |
ADP ribosylation factor 1 |
eukaryotic translation elongation factor 1 gamma |
- Synthesis of PIPs at the plasma membrane
- Synthesis of PIPs at the Golgi membrane
- Nef Mediated CD4 Down-regulation
- trans-Golgi Network Vesicle Budding
- MHC class II antigen presentation
- Lysosome Vesicle Biogenesis
- Golgi Associated Vesicle Biogenesis
- COPI-mediated anterograde transport
- COPI-dependent Golgi-to-ER retrograde traffic
- Intra-Golgi traffic
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
|
- Eukaryotic Translation Elongation
|
- 1,3-Propandiol
- Guanosine-3'-Monophosphate-5'-Diphosphate
- Guanosine-5'-Triphosphate
- Guanosine-5'-Diphosphate
- Brefeldin A
- Myristic acid
- Glycerin
|
|
|
|
AXL and TYRO3 |
AXL receptor tyrosine kinase |
TYRO3 protein tyrosine kinase |
|
|
|
|
|
|
AXL and EGFR |
AXL receptor tyrosine kinase |
epidermal growth factor receptor |
|
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- EGFR Transactivation by Gastrin
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signal transduction by L1
- Constitutive Signaling by EGFRvIII
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- PTK6 promotes HIF1A stabilization
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Extra-nuclear estrogen signaling
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- HCMV Early Events
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
|
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Alvocidib
- IGN311
- Matuzumab
- Vandetanib
- Rindopepimut
- Canertinib
- Pelitinib
- Varlitinib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
- Osimertinib
- Necitumumab
- Depatuxizumab mafodotin
- Icotinib
- Neratinib
- Zalutumumab
- Brigatinib
- Olmutinib
|
|
- Choriocarcinoma
- Gastric cancer
- Bladder cancer
- Oral cancer
- Glioma
- Laryngeal cancer
- Cervical cancer
- Esophageal cancer
|
AXL and SRC |
AXL receptor tyrosine kinase |
SRC proto-oncogene, non-receptor tyrosine kinase |
|
- Signaling by ERBB2
- Nuclear signaling by ERBB4
- Downregulation of ERBB4 signaling
- PIP3 activates AKT signaling
- GAB1 signalosome
- Downstream signal transduction
- Constitutive Signaling by Aberrant PI3K in Cancer
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- G alpha (s) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Regulation of commissural axon pathfinding by SLIT and ROBO
- RAF activation
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PTK2 signaling
- InlA-mediated entry of Listeria monocytogenes into host cells
- Regulation of RUNX1 Expression and Activity
- RUNX2 regulates osteoblast differentiation
- Regulation of RUNX3 expression and activity
- Extra-nuclear estrogen signaling
- Activated NTRK2 signals through FYN
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- Long-term potentiation
- Signaling downstream of RAS mutants
|
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- XL228
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
- Nintedanib
|
|
|
AXL and GAS6 |
AXL receptor tyrosine kinase |
growth arrest specific 6 |
|
- Platelet degranulation
- Gamma-carboxylation of protein precursors
- Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
- Removal of aminoterminal propeptides from gamma-carboxylated proteins
- Cell surface interactions at the vascular wall
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- Post-translational protein phosphorylation
|
|
|
|
|
AXL and LCK |
AXL receptor tyrosine kinase |
LCK proto-oncogene, Src family tyrosine kinase |
|
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Nef and signal transduction
- Nef Mediated CD4 Down-regulation
- Downstream TCR signaling
- Phosphorylation of CD3 and TCR zeta chains
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- PECAM1 interactions
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- DAP12 signaling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- CTLA4 inhibitory signaling
- PD-1 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Interleukin-2 signaling
|
|
- Dasatinib
- {4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid
- Staurosporine
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- (4-{2-Acetylamino-2-[1-(3-Carbamoyl-4-Cyclohexylmethoxy-Phenyl)-Ethylcarbamoyl}-Ethyl}-2-Phosphono-Phenoxy)-Acetic Acid
- Phosphoaminophosphonic Acid-Adenylate Ester
- 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
- 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
- N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
- Ponatinib
- Nintedanib
|
|
- Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
|
AZU1 and CLEC4G |
azurocidin 1 |
C-type lectin domain family 4 member G |
|
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
|
|
|
B2M and HLA-B |
beta-2-microglobulin |
major histocompatibility complex, class I, B |
- ER-Phagosome pathway
- ER-Phagosome pathway
- Endosomal/Vacuolar pathway
- Nef mediated downregulation of MHC class I complex cell surface expression
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- DAP12 interactions
- DAP12 signaling
- DAP12 signaling
- Neutrophil degranulation
- Interferon gamma signaling
- Modulation by Mtb of host immune system
- Amyloid fiber formation
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
|
- ER-Phagosome pathway
- ER-Phagosome pathway
- Endosomal/Vacuolar pathway
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Neutrophil degranulation
- Interferon gamma signaling
- Interferon alpha/beta signaling
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
|
- Doxycycline
- 3-Indolebutyric Acid
- N-Formylmethionine
- Copper
|
|
|
|
B2M and CXCR4 |
beta-2-microglobulin |
C-X-C motif chemokine receptor 4 |
- ER-Phagosome pathway
- ER-Phagosome pathway
- Endosomal/Vacuolar pathway
- Nef mediated downregulation of MHC class I complex cell surface expression
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- DAP12 interactions
- DAP12 signaling
- DAP12 signaling
- Neutrophil degranulation
- Interferon gamma signaling
- Modulation by Mtb of host immune system
- Amyloid fiber formation
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
|
- Binding and entry of HIV virion
- Signaling by ROBO receptors
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
|
- Doxycycline
- 3-Indolebutyric Acid
- N-Formylmethionine
- Copper
|
- Framycetin
- AMD-070
- Plerixafor
|
|
- Chemokine receptor defect, including the following disease: WHIM syndrome
|
B2M and LILRB1 |
beta-2-microglobulin |
leukocyte immunoglobulin like receptor B1 |
- ER-Phagosome pathway
- ER-Phagosome pathway
- Endosomal/Vacuolar pathway
- Nef mediated downregulation of MHC class I complex cell surface expression
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- DAP12 interactions
- DAP12 signaling
- DAP12 signaling
- Neutrophil degranulation
- Interferon gamma signaling
- Modulation by Mtb of host immune system
- Amyloid fiber formation
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
|
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
- Doxycycline
- 3-Indolebutyric Acid
- N-Formylmethionine
- Copper
|
|
|
|
BAD and PIM2 |
BCL2 associated agonist of cell death |
Pim-2 proto-oncogene, serine/threonine kinase |
- Activation of BAD and translocation to mitochondria
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- NRAGE signals death through JNK
- AKT phosphorylates targets in the cytosol
- Constitutive Signaling by AKT1 E17K in Cancer
|
|
|
|
|
|
BAD and BCL2 |
BCL2 associated agonist of cell death |
BCL2 apoptosis regulator |
- Activation of BAD and translocation to mitochondria
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- NRAGE signals death through JNK
- AKT phosphorylates targets in the cytosol
- Constitutive Signaling by AKT1 E17K in Cancer
|
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
- Estrogen-dependent gene expression
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
- S-8184
- Paclitaxel docosahexaenoic acid
- Glycine betaine
- Eribulin
- Dexibuprofen
- Venetoclax
- Obatoclax
- Navitoclax
|
|
- Choriocarcinoma
- Gastric cancer
- Chronic lymphocytic leukemia (CLL)
- Small cell lung cancer
- Kaposi's sarcoma
- Nasopharyngeal cancer
- Cervical cancer
|
BAD and BCL2L1 |
BCL2 associated agonist of cell death |
BCL2 like 1 |
- Activation of BAD and translocation to mitochondria
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- NRAGE signals death through JNK
- AKT phosphorylates targets in the cytosol
- Constitutive Signaling by AKT1 E17K in Cancer
|
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
|
|
- 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID
- Gossypol
|
|
|
BCL2 and BCL2L1 |
BCL2 apoptosis regulator |
BCL2 like 1 |
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
- Estrogen-dependent gene expression
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
- S-8184
- Paclitaxel docosahexaenoic acid
- Glycine betaine
- Eribulin
- Dexibuprofen
- Venetoclax
- Obatoclax
- Navitoclax
|
- 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID
- Gossypol
|
- Choriocarcinoma
- Gastric cancer
- Chronic lymphocytic leukemia (CLL)
- Small cell lung cancer
- Kaposi's sarcoma
- Nasopharyngeal cancer
- Cervical cancer
|
|
BCL2 and BNIP3 |
BCL2 apoptosis regulator |
BCL2 interacting protein 3 |
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
- Estrogen-dependent gene expression
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
- S-8184
- Paclitaxel docosahexaenoic acid
- Glycine betaine
- Eribulin
- Dexibuprofen
- Venetoclax
- Obatoclax
- Navitoclax
|
|
- Choriocarcinoma
- Gastric cancer
- Chronic lymphocytic leukemia (CLL)
- Small cell lung cancer
- Kaposi's sarcoma
- Nasopharyngeal cancer
- Cervical cancer
|
|
BCL2 and BNIP3L |
BCL2 apoptosis regulator |
BCL2 interacting protein 3 like |
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
- Estrogen-dependent gene expression
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
- S-8184
- Paclitaxel docosahexaenoic acid
- Glycine betaine
- Eribulin
- Dexibuprofen
- Venetoclax
- Obatoclax
- Navitoclax
|
|
- Choriocarcinoma
- Gastric cancer
- Chronic lymphocytic leukemia (CLL)
- Small cell lung cancer
- Kaposi's sarcoma
- Nasopharyngeal cancer
- Cervical cancer
|
|
BCL2 and NMT2 |
BCL2 apoptosis regulator |
N-myristoyltransferase 2 |
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
- Estrogen-dependent gene expression
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- Membrane binding and targetting of GAG proteins
- Inactivation, recovery and regulation of the phototransduction cascade
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
- S-8184
- Paclitaxel docosahexaenoic acid
- Glycine betaine
- Eribulin
- Dexibuprofen
- Venetoclax
- Obatoclax
- Navitoclax
|
- Myristoyl-Coa
- S-(2-Oxo)Pentadecylcoa
- 1-(CYCLOHEXYLAMINO)-3-(6-METHYL-3,4-DIHYDRO-1H-CARBAZOL-9(2H)-YL)PROPAN-2-OL
- (Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE
|
- Choriocarcinoma
- Gastric cancer
- Chronic lymphocytic leukemia (CLL)
- Small cell lung cancer
- Kaposi's sarcoma
- Nasopharyngeal cancer
- Cervical cancer
|
|
BCL2 and HSPA1A |
BCL2 apoptosis regulator |
heat shock protein family A (Hsp70) member 1A |
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
- Estrogen-dependent gene expression
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- Viral RNP Complexes in the Host Cell Nucleus
- Regulation of HSF1-mediated heat shock response
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Attenuation phase
- HSF1-dependent transactivation
- AUF1 (hnRNP D0) binds and destabilizes mRNA
- Neutrophil degranulation
- Regulation of HSF1-mediated heat shock response
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Attenuation phase
- HSF1-dependent transactivation
- Neutrophil degranulation
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
- S-8184
- Paclitaxel docosahexaenoic acid
- Glycine betaine
- Eribulin
- Dexibuprofen
- Venetoclax
- Obatoclax
- Navitoclax
|
|
- Choriocarcinoma
- Gastric cancer
- Chronic lymphocytic leukemia (CLL)
- Small cell lung cancer
- Kaposi's sarcoma
- Nasopharyngeal cancer
- Cervical cancer
|
|
BCL2 and PMAIP1 |
BCL2 apoptosis regulator |
phorbol-12-myristate-13-acetate-induced protein 1 |
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
- Estrogen-dependent gene expression
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- Activation of NOXA and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
- S-8184
- Paclitaxel docosahexaenoic acid
- Glycine betaine
- Eribulin
- Dexibuprofen
- Venetoclax
- Obatoclax
- Navitoclax
|
|
- Choriocarcinoma
- Gastric cancer
- Chronic lymphocytic leukemia (CLL)
- Small cell lung cancer
- Kaposi's sarcoma
- Nasopharyngeal cancer
- Cervical cancer
|
|
BCL2 and PML |
BCL2 apoptosis regulator |
promyelocytic leukemia |
- Activation of BAD and translocation to mitochondria
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-4 and Interleukin-13 signaling
- The NLRP1 inflammasome
- Estrogen-dependent gene expression
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of ubiquitinylation proteins
- Regulation of TP53 Activity through Acetylation
- Interferon gamma signaling
- Regulation of RUNX1 Expression and Activity
- Regulation of PTEN localization
- HCMV Early Events
|
- Ibuprofen
- Paclitaxel
- Docetaxel
- Rasagiline
- S-8184
- Paclitaxel docosahexaenoic acid
- Glycine betaine
- Eribulin
- Dexibuprofen
- Venetoclax
- Obatoclax
- Navitoclax
|
|
- Choriocarcinoma
- Gastric cancer
- Chronic lymphocytic leukemia (CLL)
- Small cell lung cancer
- Kaposi's sarcoma
- Nasopharyngeal cancer
- Cervical cancer
|
- Acute myeloid leukemia (AML)
|